Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 21, 2005
- Banyu Aiming for Annual Sales of \350 Bil. at Early Date: Mr Hirate
March 21, 2005
- PRESS SEMINAR
March 21, 2005
- Meiji Seika to Enlist Help of MSs in Marketing Activities
March 21, 2005
- Zepharma on Track to Achieve Initial Business Targets
March 21, 2005
- Kanebo Aiming to Become Leader in Kampo Medicines
March 21, 2005
- Kobashou Aims to Build Nationwide Network by FY2007
March 21, 2005
- Marketing of Zione Inj to Focus on Specialists in 1st 2 Years: MPC
March 21, 2005
- OTC NEWS IN BRIEF
March 21, 2005
- BUSINESS NEWS IN BRIEF
March 21, 2005
- MEDICAL DEVICE NEWS IN BRIEF
March 21, 2005
- WEBSITE NEWS
March 21, 2005
- Annual Business Result
March 21, 2005
- Annual Business Results
March 21, 2005
- Sales of Ethical Drugs Rose 2.1% to \7.2 Tril. in 2004: IMS Japan
March 21, 2005
- Aiming for \1 Tril. in Sales in FY2011: Mr Naito of Eisai
March 14, 2005
- Sales of Pfizer Japan Increase 25.2% to \385.6 Bil.
March 14, 2005
- Committee Recommends Approval of In Vivo Diagnostic Adenosine
March 14, 2005
- Japan Pharmaceutical Roundtable-Economist Conference
March 14, 2005
- 5 Drugs Including Vfend Recommended for Approval
March 14, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…